Skip to content. | Skip to navigation

Personal tools
Log in
You are here: Home Know-who Know-how Directory From A to Z MedSciences Capital

MedSciences Capital

Business focus: Equity financing of high potential early to mid stage life sciences companies in the Netherlands.

MedSciences Capital

MedSciences Capital
Beethovenstraat 300
1070 AR  Amsterdam
Website MedSciences Capital
E-mail MedSciences Capital
T +31 (0)20 348 87 02
F +31 (0)20 348 87 50

Employees in Amsterdam: 2
Employees in R&D: 0
Year of foundation: 2000

Company Profile

MedSciences Capital is a venture capital fund that exclusively invests in companies developing diagnostics, therapeutics, or medical devices for human use. We are interested in early- to mid-stage companies with a significant growth potential. Our geographical focus is on the Benelux countries.
We may invest up to approximately € 2.5 million per company.  If your financing need goes beyond that amount, we invest together with other professional capital providers.
We actively support our portfolio companies in both strategic and operational matters, either directly or through our network.
MedSciences Capital operates as a part of Kempen & Co, a merchant bank offering capital management, corporate financing, and security trading services in a number of specialty fields, including life sciences. 

Keywords

  • Life sciences
  • Equity
  • Funding
  • Start-up financing




Document Actions
Filed under:

Find your life sciences partner in the Amsterdam BioMed Cluster

Find your life sciences partner in the Amsterdam BioMed Cluster

Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...